# US 2023/0265441 A1 · Aptamers That Bind Thiamine Analogs and Derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265441 A1
- Document ID: US20230265441A1
- Status: Published application
- Kind: A1
- Application number: 17/907,189
- Filed: 2021-03-24
- Published: 2023-08-24
- Earliest claimed: 2020-03-24
- Assignees: Meiragtx UK II Limited
- Applicants: MeiraGTx UK II Limited
- Inventors: Xuecui Guo; Alexandria Forbes; Kevin G. Liu; Ji-In Kim
- Web page: https://patentgrep.com/patent/US20230265441A1

## CPC

- C12N 15/635: {Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline}
- C12N 15/1086: {Preparation or screening of expression libraries, e.g. reporter assays}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 15/67: General methods for enhancing the expression
- C12N 15/86: Viral vectors
- C12N 2310/16: Aptamers
- C12N 2310/3519: Fusion with another nucleic acid
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2320/11: for the determination of target sites, i.e. of active nucleic acids
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2830/002: inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure relates to oligonucleotide aptamers that bind to certain small molecules including thiamine analogs and derivatives and methods of generating aptamers that bind to the small molecules. Also contemplated are riboswitches and polynucleotide cassettes comprising the aptamers disclosed herein. Further provided are methods of using said aptamers, riboswitches, and/or polynucleotide for the regulation of target genes, including therapeutic genes. Also provided herein are small molecules that are modulators of target gene expression where the target gene contains a riboswitch comprising an aptamer described herein.

## Claims

### Claim 1

A polynucleotide cassette for regulating the expression of a target gene, wherein the polynucleotide cassette comprises a sequence encoding an aptamer that binds to a small molecule, wherein the aptamer encoding sequence comprises
ACX1GGGGTCCGGCX2TX3TTCATTTGGCX4CCGGTGAGAX5X6AX7ACC
CTTX8X9X10X11CCTGTTX12ACGGATAATGCCGCX13GCAGGGAGT (
SEQ ID NO:1),
and wherein:
X1 is A or G;
X2 is C or no nucleotide;
X3 is T or no nucleotide;
X4 is A or G;
X5 is any nucleotide;
X6 is any nucleotide;
X7 is any nucleotide;
X8 is any nucleotide;
X9 is C, G, or T;
X10 is any nucleotide;
X11 is A or T;
X12 is C or T; and
X13 is C or T.

### Claim 2

A polynucleotide cassette for regulating the expression of a target gene, wherein the polynucleotide cassette comprises a sequence encoding an aptamer that binds to a small molecule, wherein the aptamer encoding sequence comprises
ACX1GGGGTCCGGCX2TX3TTCATTTGGCGCCGGTGAGAX5X6AX7ACCC
TTX8X9X10X11CCTGTTX12ACGGATAATGCCGCX13GCAGGGAGT (S
EQ ID NO:2)
and wherein:
X1 is A or G;
X2 is C or no nucleotide;
X3 is T or no nucleotide;
X5 is G or T;
X6 is C or T;
X7 is C or T;
X8 is any nucleotide;
X9 is G or T;
X10 is A, G, or T;
X11 is A or T;
X12 is C or T; and
X13 is C or T.

### Claim 3

A polynucleotide cassette for regulating the expression of a target gene, wherein the polynucleotide cassette comprises a sequence encoding an aptamer that binds to a small molecule, wherein the aptamer encoding sequence comprises
ACAGGGGTCCGGCCTTTTCATTTGGCGCCGGTGAGAGCACACCCTTTGAA
CCTGTTX12ACGGATAATGCCGCX13GCAGGGAGT (SEQ ID NO:3)
and
wherein:
X12 is C or T; and
X13 is C or T.

### Claim 4

A polynucleotide cassette for regulating the expression of a target gene, wherein the polynucleotide cassette comprises a sequence encoding an aptamer that binds to a small molecule, wherein the aptamer encoding sequence comprises
ACX1GGGGTCCGGCCTTTTCATTTGGCGCCGGTGAGAGCACACCCTTX8X 9X10X11CCTGTTTACGGATAATGCCGCCGCAGGGAGT(SEQ ID NO:4
)
and
wherein
X1 is A or G;
X8 is any nucleotide;
X9 is G or T;
X10 is A, G, or T; and
X11 is A or T.

### Claim 5

A polynucleotide cassette for regulating the expression of a target gene, wherein the polynucleotide cassette comprises a sequence encoding an aptamer that binds to a small molecule, wherein the aptamer encoding sequence comprises
ACAGGGGTCCGGCCTTTTCATTTGGCGCCGGTGAGAX5X6AX7ACCCTTT
GAACCTGTTTACGGATAATGCCGCCGCAGGGAGT (SEQ ID NO:5)
and wherein:
X5 is G or T;
X6 is C or T; and
X7 is C or T.

### Claim 6

A polynucleotide cassette for regulating the expression of a target gene, wherein the polynucleotide cassette comprises a sequence encoding an aptamer that binds to a small molecule, wherein the aptamer encoding sequence comprises
ACAGGGGTCCGGCCTTTTCATTTGGCX4CCGGTGAGAX5X6AX7ACCCTT
X8X9X10ACCTGTTCACGGATAATGCCGCTGCAGGGAGT (SEQ ID NO
:6)
and
wherein:
X4 is A or G;
X5 is any nucleotide;
X6 is any nucleotide;
X7 is any nucleotide;
X8 is any nucleotide;
X9 is C or G; and
X10 is any nucleotide.

### Claim 7

A polynucleotide cassette for regulating the expression of a target gene, wherein the polynucleotide cassette comprises a sequence encoding an aptamer that binds to a small molecule, wherein the aptamer encoding sequence comprises a sequence that is at least 95% identical to a sequence selected from the group consisting of SEQ ID NOs:7-36.

### Claim 8 (depends on 7)

The polynucleotide cassette of claim 7, wherein the aptamer encoding sequence is selected from the group consisting of SEQ ID NOs:7-36.

### Claim 9 (depends on 8)

The polynucleotide cassette of claim 8, wherein the aptamer encoding sequence is selected from the group consisting of SEQ ID NOs:8, 9, 14-18, 21, 25, 26, and 30.

### Claim 10 (depends on 9)

The polynucleotide cassette of claim 9, wherein the aptamer encoding sequence comprises a sequence selected from the group consisting of SEQ ID NOs: 9, 14, and 26.

### Claim 11

A nucleic acid sequence encoding an aptamer that binds to a small molecule, wherein the aptamer encoding sequence comprises
ACX1GGGGTCCGGCX2TX3TTCATTTGGCX4CCGGTGAGAX5X6AX7ACC
CTTX8X9X10X11CCTGTTX12ACGGATAATGCCGCX13GCAGGGAGT (
SEQ ID NO:1)
and wherein:
X1 is A or G;
X2 is C or no nucleotide;
X3 is T or no nucleotide;
X4 is A or G;
X5 is any nucleotide;
X6 is any nucleotide;
X7 is any nucleotide;
X8 is any nucleotide;
X9 is C, G, or T;
X10 is any nucleotide;
X11 is A or T;
X12 is C or T; and
X13 is C or T.

### Claim 12 (depends on 11)

The nucleic acid sequence of claim 11, wherein the aptamer encoding sequence has one or more of the following properties: X1 is not A; X2 is not C; X3 is not T; X4 is not G; X5 is not G; X6 is not C; X7 is not C; X8 is not T; X9 is not G; X10 is not A; X11 is not A; X12 is not T; and X13 is not C.

### Claim 13 (depends on 11)

The nucleic acid sequence of claim 11, wherein all of the following are not simultaneously present in the aptamer encoding sequence: X1 is A; X2 is C; X3 is T; X4 is G; X5 is G; X6 is C; X7 is C; X8 is T; X9 is G; X10 is A; X11 is A; X12 is T; and X13 is C.

### Claim 14

A nucleic acid sequence encoding an aptamer that binds to a small molecule, wherein the aptamer encoding sequence comprises
ACX1GGGGTCCGGCX2TX3TTCATTTGGCGCCGGTGAGAX5X6AX7ACCC
TTX8X9X10X11CCTGTTX12ACGGATAATGCCGCX13GCAGGGAGT (S
EQ ID NO:2)
and wherein:
X1 is A or G;
X2 is C or no nucleotide;
X3 is T or no nucleotide;
X5 is G or T;
X6 is C or T;
X7 is C or T;
X8 is any nucleotide;
X9 is G or T;
X10 is A, G, or T;
X11 is A or T;
X12 is C or T; and
X13 is C or T.

### Claim 15 (depends on 14)

The nucleic acid sequence of claim 14, wherein the aptamer encoding sequence has one or more of the following properties: X1 is not A; X2 is not C; X3 is not T; X4 is not G; X5 is not G; X6 is not C; X7 is not C; X8 is not T; X9 is not G; X10 is not A; X11 is not A; X12 is not T; and X13 is not C.

### Claim 16 (depends on 14)

The nucleic acid sequence of claim 14, wherein all of the following are not simultaneously present in the aptamer encoding sequence: X1 is A; X2 is C; X3 is T; X5 is G; X6 is C; X7 is C; X8 is T; X9 is G; X10 is A; X11 is A; X12 is T; and X13 is C.

### Claim 17

A nucleic acid sequence encoding an aptamer that binds to a small molecule, wherein the aptamer encoding sequence comprises
ACAGGGGTCCGGCCTTTTCATTTGGCGCCGGTGAGAGCACACCCTTTGAA
CCTGTTX12ACGGATAATGCCGCX13GCAGGGAGT (SEQ ID NO:3)
and wherein:
X12 is C or T; and
X13 is C or T.

### Claim 18 (depends on 17)

The nucleic acid sequence of claim 17, wherein the aptamer encoding sequence has one or more of the following properties: X12 is not T; and X13 is not C.

### Claim 19 (depends on 17)

The nucleic acid sequence of claim 17, wherein all of the following are not simultaneously present in the aptamer encoding sequence: X12 is T and X13 is C.

### Claim 20

A nucleic acid sequence encoding an aptamer that binds to a small molecule, wherein the aptamer encoding sequence comprises
ACX1GGGGTCCGGCCTTTTCATTTGGCGCCGGTGAGAGCACACCCTTX8X 9X10X11CCTGTTTACGGATAATGCCGCCGCAGGGAGT(SEQ ID NO:4
)
and
wherein:
X1 is A or G;
X8 is any nucleotide;
X9 is G or T;
X10 is A, G, or T; and
X11 is A or T.

### Claim 21 (depends on 20)

The nucleic acid sequence of claim 20, wherein the aptamer encoding sequence has one or more of the following properties: X1 is not A; X8 is not T; X9 is not G; X10 is not A; X11 is not A.

### Claim 22 (depends on 20)

The nucleic acid sequence of claim 20, wherein all of the following are not simultaneously present in the aptamer encoding sequence: X1 is A; X8 is T; X9 is G; X10 is A; X11 is A; X12 is T; and X13 is C.

### Claim 23

A nucleic acid sequence encoding an aptamer that binds to a small molecule, wherein the aptamer encoding sequence comprises
ACAGGGGTCCGGCCTTTTCATTTGGCGCCGGTGAGAX5X6AX7ACCCTTT
GAACCTGTTTACGGATAATGCCGCCGCAGGGAGT (SEQ ID NO:5)
and wherein:
X5 is G or T;
X6 is C or T; and
X7 is C or T.

### Claim 24 (depends on 23)

The nucleic acid sequence of claim 23, wherein the aptamer encoding sequence has one or more of the following properties: X5 is not G; X6 is not C; and X7 is not C.

### Claim 25 (depends on 23)

The nucleic acid sequence of claim 23, wherein all of the following are not simultaneously present in the aptamer encoding sequence: X5 is G; X6 is C; and X7 is C.

### Claim 26

A nucleic acid sequence encoding an aptamer that binds to a small molecule, wherein the aptamer encoding sequence comprises
ACAGGGGTCCGGCCTTTTCATTTGGCX4CCGGTGAGAX5X6AX7ACCCTT
X8X9X10ACCTGTTCACGGATAATGCCGCTGCAGGGAGT (SEQ ID NO
:6)
and
wherein:
X4 is A or G;
X5 is any nucleotide;
X6 is any nucleotide;
X7 is any nucleotide;
X8 is any nucleotide;
X9 is C or G; and
X10 is any nucleotide.

### Claim 27

A nucleic acid sequence encoding an aptamer that binds to a small molecule, wherein the aptamer encoding sequence comprises a sequence that is at least 95% identical to a sequence selected from the group consisting of SEQ ID NOs:7-36.

### Claim 28 (depends on 27)

The nucleic acid sequence of claim 27, wherein the aptamer encoding sequence is selected from the group consisting of SEQ ID NOs:7-36.

### Claim 29 (depends on 28)

The nucleic acid sequence of claim 28, wherein the aptamer encoding sequence is selected from the group consisting of SEQ ID NOs:8, 9, 14-18, 21, 25, 26, and 30.

### Claim 30 (depends on 29)

The nucleic acid sequence of claim 29, wherein the aptamer encoding sequence comprises a sequence selected from the group consisting of SEQ ID NOs: 9, 14, and 26.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The polynucleotide cassette of any one of claims 1-10 or the nucleic acid sequence of any one of claims 11-30, wherein the aptamer binds to, or otherwise responds to the presence of, a small molecule having the structure according to any one of:
a) Formula I:
wherein:
R1 is selected from the group consisting of OH, amino, F, C1, Br, phosphate, pyrophosphate,
—O—C(═O)—C1-C6 alkyl, —O—C(═O)—C2-C6 alkenyl, —O—C(═O)—phenyl, —O—C(═O)—heterocycle, —O—C(═O)—O—C1-C6 alkyl, —O—C(═O)—O—C2-C6 alkenyl, —O—C(═O)—O—phenyl, and —O—C(═O)—O—heterocycle;
b) Formula II: wherein:
R2 is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, —(CH2)n—R6,
—C(═O)—R4, —C(═O)—O—R4, —CHR5—O—C(═O)—R4, —S—C1-C6 alkyl, —S—C2-C6 alkenyl, —S—heterocycle, and —S—CH2—heterocycle;
or R2 is —S—[Formula II] such that the compound forms a dimer of two molecules of Formula II connected through a disulfide (—S—S—) linkage;
R3 is selected from the group consisting of OH, amino, F, Cl, Br, phosphate, pyrophosphate,
—O—C(═O)—C1-C6 alkyl, —O—C(═O)—C1-C6 alkenyl, —O—C(═O)—phenyl, —O—C(═O)—heterocycle, —O—C(═O)—O—C1-C6 alkyl, —O—C(═O)—O—C1-C6 alkenyl, —O—C(═O)—O—phenyl, —O—C(═O)—O—heterocycle;
R4 is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C3-C7 cycloalkyl, C6-C10 bicyclyl, C9-C14 tricyclyl, -(C1-C6 alkyl)-aryl, -(C2-C6 alkenyl)-aryl, aryl, heteroaryl and hetercyclyl;
R5 is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C3-C7 cycloalkyl, aryl, heteroaryl and hetercyclyl;
R6 is hydroxyl, amino, amido, C1-C6 alkoxy, C3-C7 cycloalkyl, C6-C10 bicylcyl, aryl, heteroaryl and hetercyclyl; and
n is 1 to 8;
and wherein each of the alkyl, alkenyl, cycloalkyl, bicyclyl, tricyclyl, aryl, heteroaryl and hetercyclyl groups may be unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, hydroxyl, amino, cyano, amido, sulfonamide, nitro, —SH, C1-C6 alkyl, C2-C6 alkenyl, C3-C7 cycloalkyl, C6-C10 bicyclyl, C1-C6 haloalkyl, C1-C6 perhaloalkyl, —O—(C1-C6 alkyl), O-(C3-C7 cycloalkyl), —O—(C1-C6 haloalkyl), —O—(C1-C6 perhaloalkyl), aryl, —O—aryl, -(C1-C6 alkyl)-aryl, —O—(C1-C6 alkyl)-aryl, —S—(C1-C6 alkyl), —S—(C3-C7 cycloalkyl), —S—(C1-C6 haloalkyl), —S—(C1-C6 perhaloalkyl), —S—aryl, —S—(C1-C6 alkyl)-aryl, heteroaryl and hetercyclyl;
c) Formula III: wherein:
R2 is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, —(CH2)n—R6,
—C(═O)—R4, —C(═O)—O—R4, —CHR5—O—C(═O)—R4, —S—C1-C6 alkyl, —S—C2-C6 alkenyl, —S—heterocycle, and —S—CH2—heterocycle;
R31 is selected from the group consisting of OH and phosphate;
R4 is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C3-C7 cycloalkyl, C6-C10 bicyclyl, C9-C14 tricyclyl, -(C1-C6 alkyl)-aryl, -(C2-C6 alkenyl)-aryl, aryl, heteroaryl and hetercyclyl;
R5 is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C3-C7 cycloalkyl, aryl, heteroaryl and hetercyclyl;
R6 is hydroxyl, amino, amido, C1-C6 alkoxy, C3-C7 cycloalkyl, C6-C10 bicylcyl, aryl, heteroaryl and hetercyclyl; and
n is 1 to 8;
and wherein each of the alkyl, alkenyl, cycloalkyl, bicyclyl, tricyclyl, aryl, heteroaryl and hetercyclyl groups may be unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, hydroxyl, amino, cyano, amido, sulfonamide, nitro, —SH, C1-C6 alkyl, C2-C6 alkenyl, C3-C7 cycloalkyl, C6-C10 bicyclyl, C1-C6 haloalkyl, C1-C6 perhaloalkyl, —O—(C1-C6 alkyl), O-(C3-C7 cycloalkyl), —O—(C1-C6 haloalkyl), —O—(C1-C6 perhaloalkyl), aryl, —O—aryl, -(C1-C6 alkyl)-aryl, —O—(C1-C6 alkyl)-aryl, —S—(C1-C6 alkyl), —S—(C3-C7 cycloalkyl), —S—(C1-C6 haloalkyl), —S—(C1-C6 perhaloalkyl), —S—aryl, —S—(C1-C6 alkyl)-aryl, heteroaryl and hetercyclyl;
d) Formula IV: wherein:
R4 is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C3-C7 cycloalkyl, C6-C10 bicyclyl, C9-C14 tricyclyl, -(C1-C6 alkyl)-aryl, -(C2-C6 alkenyl)-aryl, aryl, heteroaryl and hetercyclyl;
R5 is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C3-C7 cycloalkyl, aryl, heteroaryl and hetercyclyl;
and wherein each of the alkyl, alkenyl, cycloalkyl, bicyclyl, tricyclyl, aryl, heteroaryl and hetercyclyl groups may be unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, hydroxyl, amino, cyano, amido, sulfonamide, nitro, —SH, C1-C6 alkyl, C2-C6 alkenyl, C3-C7 cycloalkyl, C6-C10 bicyclyl, C1-C6 haloalkyl, C1-C6 perhaloalkyl, —O—(C1-C6 alkyl), O-(C3-C7 cycloalkyl), —O—(C1-C6 haloalkyl), —O—(C1-C6 perhaloalkyl), aryl, —O—aryl, -(C1-C6 alkyl)-aryl, —O—(C1-C6 alkyl)-aryl, —S—(C1-C6 alkyl), —S—(C3-C7 cycloalkyl), —S—(C1-C6 haloalkyl), —S—(C1-C6 perhaloalkyl), —S—aryl, —S—(C1-C6 alkyl)-aryl, heteroaryl and hetercyclyl;
e) Formula V: wherein:
R4 is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C3-C7 cycloalkyl, C6-C10 bicyclyl, C9-C14 tricyclyl, -(C1-C6 alkyl)-aryl, -(C2-C6 alkenyl)-aryl, aryl, heteroaryl and hetercyclyl;
and wherein each of the alkyl, alkenyl, cycloalkyl, bicyclyl, tricyclyl, aryl, heteroaryl and hetercyclyl groups may be unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, hydroxyl, amino, cyano, amido, sulfonamide, nitro, —SH, C1-C6 alkyl, C2-C6 alkenyl, C3-C7 cycloalkyl, C6-C10 bicyclyl, C1-C6 haloalkyl, C1-C6 perhaloalkyl, —O—(C1-C6 alkyl), O-(C3-C7 cycloalkyl), —O—(C1-C6 haloalkyl), —O—(C1-C6 perhaloalkyl), aryl, —O—aryl, -(C1-C6 alkyl)-aryl, —O—(C1-C6 alkyl)-aryl, —S—(C1-C6 alkyl), —S—(C3-C7 cycloalkyl), —S—(C1-C6 haloalkyl), —S—(C1-C6 perhaloalkyl), —S—aryl, —S—(C1-C6 alkyl)-aryl, heteroaryl and hetercyclyl;
f) Formula VI: wherein:
R4 is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C3-C7 cycloalkyl, C6-C10 bicyclyl, C9-C14 tricyclyl, -(C1-C6 alkyl)-aryl, -(C2-C6 alkenyl)-aryl, aryl, heteroaryl and hetercyclyl;
and wherein each of the alkyl, alkenyl, cycloalkyl, bicyclyl, tricyclyl, aryl, heteroaryl and hetercyclyl groups may be unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, hydroxyl, amino, cyano, amido, sulfonamide, nitro, —SH, C1-C6 alkyl, C2-C6 alkenyl, C3-C7 cycloalkyl, C6-C10 bicyclyl, C1-C6 haloalkyl, C1-C6 perhaloalkyl, —O—(C1-C6 alkyl), O-(C3-C7 cycloalkyl), —O—(C1-C6 haloalkyl), —O—(C1-C6 perhaloalkyl), aryl, —O—aryl, -(C1-C6 alkyl)-aryl, —O—(C1-C6 alkyl)-aryl, —S—(C1-C6 alkyl), —S—(C3-C7 cycloalkyl), —S—(C1-C6 haloalkyl), —S—(C1-C6 perhaloalkyl), —S—aryl, —S—(C1-C6 alkyl)-aryl, heteroaryl and hetercyclyl;
g) Formula VII
wherein:
each R7 is independently selected from halogen, hydroxyl, amino, cyano, amido, sulfonamide, nitro, —SH, C1-C6 alkyl, C2-C6 alkenyl, C3-C7 cycloalkyl, C6-C10 bicyclyl, C1-C6 haloalkyl, C1-C6 perhaloalkyl, —O—(C1-C6 alkyl), O-(C3-C7 cycloalkyl), —O—(C1-C6 haloalkyl), —O—(C1-C6 perhaloalkyl), aryl, —O—aryl, -(C1-C6 alkyl)-aryl, —O—(C1-C6 alkyl)-aryl, —S—(C1-C6 alkyl), —S—(C3-C7 cycloalkyl), —S—(C1-C6 haloalkyl), —S—(C1-C6 perhaloalkyl), —S—aryl, —S—(C1-C6 alkyl)-aryl, heteroaryl and hetercyclyl;
additionally or alternatively, two adjacent R7 groups may be taken together to form a fused 5- or 6-membered aromatic or non-aromatic ring, which contains 0 to 2 ring heteroatoms, and which is unsubstituted or is substituted by up to four substituents selected from halogen, hydroxyl, amino, cyano, amido, sulfonamide, nitro, —SH, C1-C6 alkyl, C2-C6 alkenyl, C3-C7 cycloalkyl, C6-C10 bicyclyl, C1-C6 haloalkyl, C1-C6 perhaloalkyl, —O—(C1-C6 alkyl), O-(C3-C7 cycloalkyl), —O—(C1-C6 haloalkyl), —O—(C1-C6 perhaloalkyl), aryl, —O—aryl, -(C1-C6 alkyl)-aryl, —O—(C1-C6 alkyl)-aryl, —S—(C1-C6 alkyl), —S—(C3-C7 cycloalkyl), —S—(C1-C6 haloalkyl), —S—(C1-C6 perhaloalkyl), —S—aryl, —S—(C1-C6 alkyl)-aryl, heteroaryl and hetercyclyl; and
m is 0, 1, 2, 3 or 4; and
h) Formula VIII
wherein:
each R8 is independently selected from halogen, hydroxyl, amino, cyano, amido, sulfonamide, nitro, —SH, C1-C6 alkyl, C2-C6 alkenyl, C3-C7 cycloalkyl, C6-C10 bicyclyl, C1-C6 haloalkyl, C1-C6 perhaloalkyl, —O—(C1-C6 alkyl), O-(C3-C7 cycloalkyl), —O—(C1-C6 haloalkyl), —O—(C1-C6 perhaloalkyl), aryl, —O—aryl, -(C1-C6 alkyl)-aryl, —O—(C1-C6 alkyl)-aryl, —S—(C1-C6 alkyl), —S—(C3-C7 cycloalkyl), —S—(C1-C6 haloalkyl), —S—(C1-C6 perhaloalkyl), —S—aryl, —S—(C1-C6 alkyl)-aryl, heteroaryl and hetercyclyl;
additionally or alternatively, two adjacent R8 groups may be taken together to form a fused 5- or 6-membered aromatic or non-aromatic ring, which contains 0 to 2 ring heteroatoms, and which is unsubstituted or is substituted by up to four substituents selected from halogen, hydroxyl, amino, cyano, amido, sulfonamide, nitro, —SH, C1-C6 alkyl, C2-C6 alkenyl, C3-C7 cycloalkyl, C6-C10 bicyclyl, C1-C6 haloalkyl, C1-C6 perhaloalkyl, —O—(C1-C6 alkyl), O-(C3-C7 cycloalkyl), —O—(C1-C6 haloalkyl), —O—(C1-C6 perhaloalkyl), aryl, —O—aryl, -(C1-C6 alkyl)-aryl, —O—(C1-C6 alkyl)-aryl, —S—(C1-C6 alkyl), —S—(C3-C7 cycloalkyl), —S—(C1-C6 haloalkyl), —S—(C1-C6 perhaloalkyl), —S—aryl, —S—(C1-C6 alkyl)-aryl, heteroaryl and hetercyclyl;
each R9 is independently selected from halogen, hydroxyl, amino, cyano, amido, sulfonamide, nitro, —SH, C1-C6 alkyl, C2-C6 alkenyl, C3-C7 cycloalkyl, C6-C10 bicyclyl, C1-C6 haloalkyl, C1-C6 perhaloalkyl, —O—(C1-C6 alkyl), O-(C3-C7 cycloalkyl), —O—(C1-C6 haloalkyl), —O—(C1-C6 perhaloalkyl), aryl, —O—aryl, -(C1-C6 alkyl)-aryl, —O—(C1-C6 alkyl)-aryl, —S—(C1-C6 alkyl), —S—(C3-C7 cycloalkyl), —S—(C1-C6 haloalkyl), —S—(C1-C6 perhaloalkyl), —S—aryl, —S—(C1-C6 alkyl)-aryl, heteroaryl and hetercyclyl;
additionally or alternatively, two adjacent R9 groups may be taken together to form a fused 5- or 6-membered aromatic or non-aromatic ring, which contains 0 to 2 ring heteroatoms, and which is unsubstituted or is substituted by up to four substituents selected from halogen, hydroxyl, amino, cyano, amido, sulfonamide, nitro, —SH, C1-C6 alkyl, C2-C6 alkenyl, C3-C7 cycloalkyl, C6-C10 bicyclyl, C1-C6 haloalkyl, C1-C6 perhaloalkyl, —O—(C1-C6 alkyl), O-(C3-C7 cycloalkyl), —O—(C1-C6 haloalkyl), —O—(C1-C6 perhaloalkyl), aryl, —O—aryl, -(C1-C6 alkyl)-aryl, —O—(C1-C6 alkyl)-aryl, —S—(C1-C6 alkyl), —S—(C3-C7 cycloalkyl), —S—(C1-C6 haloalkyl), —S—(C1-C6 perhaloalkyl), —S—aryl, —S—(C1-C6 alkyl)-aryl, heteroaryl and hetercyclyl;
x is 0, 1, 2 or 3; and
y is 0, 1, 2, 3, or 4.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The polynucleotide cassette of any one of claims 1-10 or the nucleic acid sequence of any one of claims 11-30, wherein the aptamer binds to, or otherwise responds to the presence of, a small molecule selected from the group consisting of acefurtiamine, acetiamine, allithiamine, amprolium, beclotiamine, benfotiamine, bentiamine, bisbentiamine, cetotiamine, cycotiamine, fursultiamine, monophosphothiamine, octotiamine, oxythiamine, prosultiamine, sulbutiamine, thiamine, thiamine pyrophosphate, and vintiamol.

### Claim 33 (depends on 32)

The polynucleotide cassette or the nucleic acid sequence of claim 32, wherein the aptamer binds to, or otherwise responds to the presence of, a small molecule selected from the group consisting of benfotiamine, fursultiamine, and prosultiamine.

### Claim 34 (depends on 33)

The polynucleotide cassette or the nucleic acid sequence of claim 33, wherein the aptamer binds to, or otherwise responds to the presence of, benfotiamine.

### Claim 35 (depends on 33)

The polynucleotide cassette or the nucleic acid sequence of claim 33, wherein the aptamer binds to, or otherwise responds to the presence of, fursultiamine.

### Claim 36 (depends on 33)

The polynucleotide cassette or the nucleic acid sequence of claim 33, wherein the aptamer binds to, or otherwise responds to the presence of, prosultiamine.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The polynucleotide cassette of any one of claims 1-10 or the nucleic acid sequence of any one of claims 11-30, wherein the aptamer has reduced binding and/or shows a reduced response to thiamine pyrophosphate (TPP) compared to equimolar amounts of fursultiamine, benfotiamine or prosultiamine.

### Claim 38 (depends on 37)

The polynucleotide cassette of or the nucleic acid sequence of claim 37, wherein the aptamer is in the context of a riboswitch encoded as part of a polynucleotide cassette for regulating the expression of a target gene.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

A riboswitch for the regulation of target gene expression in response to a small molecule, wherein the riboswitch comprises the aptamer of any one of claims 1-38.

### Claim 40 (depends on 39)

The riboswitch of claim 39, the riboswitch comprises the sequence of SEQ ID NO:37.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

A polynucleotide cassette for the regulation of the expression of a target gene in response to a small molecule, the polynucleotide cassette comprising:
(c) a riboswitch; and
(d) an alternatively-spliced exon, flanked by a 5′ intron and a 3′ intron,
wherein the riboswitch comprises (i) an effector region comprising a stem that includes the 5′ splice site sequence of the 3′ intron, and (ii) the aptamer of any one of claims 1-38;
and
wherein the alternatively-spliced exon comprises a stop codon that is in-frame with the target gene when the alternatively-spliced exon is spliced into the target gene mRNA.

### Claim 42

The polynucleotide cassette of claim [0040], wherein the riboswitch comprises the sequence of SEQ ID NO:37.

### Claim 43

The polynucleotide cassette of claim [0040], wherein the polynucleotide cassette is located in the protein coding sequence of the target gene.

### Claim 44

The polynucleotide cassette of claim [0040], wherein the polynucleotide cassette is located in an untranslated region of the target gene or in an intron of the target gene.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A vector comprising the polynucleotide cassette of any one of claims 1-10, 31–38 or 41–44, the nucleic acid of any one of claims 11-38, or the riboswitch of any one of claims 39 or 40.

### Claim 46 (depends on 45)

The vector of claim 45, wherein the vector is a viral vector.

### Claim 47 (depends on 46)

The vector of claim 46, wherein the viral vector is selected from the group consisting of an adenoviral vector, an adeno-associated virus vector, and a lentiviral vector.

### Claim 48

A method for identifying an aptamer that modulates target gene expression in response to a compound of interest, the method comprising the steps of:
(i) selecting a parent aptamer;
(ii) generating a riboswitch library comprising sequences encoding the aptamer selected in step (i), wherein the aptamer encoding sequences comprise one or more randomly mutated nucleotides in one or more unpaired regions in the aptamer, wherein the mutated aptamer sequences are in the context of a riboswitch that controls the expression of a reporter gene;
(iii) screening the library from (ii) for aptamers having increased regulation of the target gene expression in response to the addition of a compound according to Formula I-VII, compared to the parent aptamer sequence;
(iv) optionally repeating steps (ii) and iii (on an aptamer identified in step (iii)).

### Claim 49 (depends on 48)

The method of claim 48, wherein the parent aptamer is a TPP aptamer and the compound of interest is a thiamine analog or derivative.

### Claim 50 (depends on 49)

The method of claim 49, wherein the TPP aptamer is selected from the Rfam TPP riboswitch family RF00059.

### Claim 51 (depends on 49, 50)

The method according to claim 49 or claim 50, wherein the thiamine analog or derivative is selected from the group consisting of Formulas I-VIII.

### Claim 52 (depends on 48, 49, 50, 51)

The method according to any one of claims 48-51, wherein the one or more unpaired regions of the aptamer sequence comprises a junction region.

### Claim 53 (depends on 48, 49, 50, 51)

The method according to any one of claims 48-51, wherein the unpaired region comprises a loop region.

### Claim 54 (depends on 48, 49, 50, 51)

The method according to any one of claims 48-51, wherein the aptamer encoding sequences further comprise one or more mutated nucleotides in a paired region.

### Claim 55 (depends on 48, 49, 50, 51)

The method according to any one of claims 48-51, wherein the aptamer encoding sequences further comprise one or more mutated nucleotides adjacent to an unpaired region.
